---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ONWARD3"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ONWARD3. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 42 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/onward3"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ONWARD3

<a id="heading-3.1.3"></a>

## 3.1.3 ONWARD3

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Objective and scientific questions in the ClinicalTrials.gov record

> “The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time.”
> “How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis?”
> “Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis?”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.1-2"></a>

#### Objective of the 48-week ONWARD3 congress analysis

> “Objective: Report maintenance of efficacy and safety through 48 weeks of total treatment in patients who completed ONWARD1 or 2 and enrolled in the ONWARD3 long-term extension”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study start, completion, and record dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-01-08”
> “Primary Completion (Estimated) 2028-11”
> “Study Completion (Estimated) 2028-11”
> “First Posted 2025-02-26”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.2-2"></a>

#### Recruitment status and last update in the ClinicalTrials.gov record

> “Last Update Posted 2026-04-13 Active, not recruiting No longer looking for participants”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.2-3"></a>

#### Countries of trial sites in the ClinicalTrials.gov record

> “This study has 268 locations”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

| Country | A site listed for the country in the record |
| --- | --- |
| United States | “Chandler, Arizona, United States, 85224” |
| Australia | “Campbelltown, South Australia, Australia, 5074” |
| Bulgaria | “Pleven, Bulgaria, 5800” |
| Canada | “Edmonton, Alberta, Canada, T6H 4J8” |
| Czechia | “Brno, Czechia, 602 00” |
| Estonia | “Tartu, Estonia, 50106” |
| France | “Nice, Alpes Maritimes, France, 6000” |
| Germany | “Münster, Germany, NRW 48149” |
| Hungary | “Debrecen, Hungary, 4027” |
| Japan | “Nagoya, Aichi-ken, Japan, 467-8602” |
| Latvia | “Riga, Latvia, LV1013” |
| Poland | “Krakow, Poland, 30-033” |
| Portugal | “Porto, Portugal, 4099-001” |
| Puerto Rico | “San Juan, Puerto Rico, 00917” |
| South Korea | “Seoul, South Korea, 3080” |
| Spain | “Barcelona, Spain, 8041” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001”
> “Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.3-2"></a>

#### Open-label period, randomized withdrawal, and return to open-label treatment in the ClinicalTrials.gov record

> “Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.3-3"></a>

#### Randomized withdrawal period and planned duration of up to 96 weeks

> “In ONWARD3, all patients received open-label envudeucitinib treatment for the first 24 weeks, regardless of their treatment assignment in ONWARD1 and 2. To assess durability and maintenance of response, the first 200 patients achieving PASI 75 at Week 24 in ONWARD3 could enter a 24-week randomized withdrawal period (RWP), in which they were randomized to receive either blinded envudeucitinib or placebo, and reassigned to open-label envudeucitinib upon loss of response or completion of the RWP, whichever occurred first.”
> “Patients not entering the randomized withdrawal period continued to receive open-label envudeucitinib treatment. ONWARD3 is designed to provide up to 96 weeks of long-term safety and efficacy data.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.3-4"></a>

#### Phase 3 long-term extension status

> “Alumis is advancing its clinical development via ONWARD3, an ongoing Phase 3 long-term extension study in moderate-to-severe plaque psoriasis, and LUMUS, a potentially pivotal Phase 2b trial in systemic lupus erythematosus, with topline data anticipated in Q3 2026.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “Males or females, age ≥18 years Completed either of the two previous (parent) studies of ESK-001 (ESK-001-016 or ESK-001-017)”
> “ESK-001 safety and tolerability were acceptable in the parent study”
> “Women of childbearing potential (WOCBP) and males who are sexually active with WOCBP must agree to adhere to highly effective methods of contraception for the entirety of the study”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Pregnant, lactating, or planning to get pregnant during the study period”
> “Any acute or chronic illness/condition or evidence of an unstable clinical condition that in the Investigator's judgment will substantially increase the risk to the patient if they continue to receive ESK-001 treatment in this extension study”
> “Deemed by the Investigator to be inappropriate for the study or unable to comply with the protocol”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.4-3"></a>

#### Ages, sexes, and healthy volunteers in the ClinicalTrials.gov record

> “Ages Eligible for Study 18 Years and older (Adult, Older Adult ) Sexes Eligible for Study All Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.4-4"></a>

#### Eligibility to enter ONWARD3 after week 24 of ONWARD1 or ONWARD2

> “Patients completing Week 24 of ONWARD1 or ONWARD2 were eligible to enter the ONWARD3 (NCT06846541) study, an ongoing long-term extension study assessing durability, maintenance of response, and long-term safety.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm and description | Intervention description |
| --- | --- | --- |
| Open-label envudeucitinib | “Experimental: Open-Label ESK-001 Open-Label ESK-001 administered as an oral tablet” | “Drug: Open-Label Envudeucitinib Open-Label ESK-001” |
| Blinded envudeucitinib | “Experimental: Blinded ESK-001 Blinded ESK-001 administered as an oral tablet” | “Blinded ESK-001 during Randomized Treatment Withdrawal Period” |
| Placebo | “Placebo Comparator: Placebo Matching placebo administered as an oral tablet” | “Placebo during Randomized Treatment Withdrawal Period” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.5-2"></a>

#### Open-label envudeucitinib 40 mg twice daily for 24 weeks regardless of parent-study treatment

> “All patients received open-label envudeucitinib for 24 weeks regardless of original treatment”
> “Open-label Envudeucitinib 40 mg BID (N = 1509)”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.5-3"></a>

#### Total envudeucitinib exposure by parent-study arm at week 48

> “Exposure to envudeucitinib varied based on parent-study assignment (i.e., 48, 32, and 24 weeks for the parent-envudeucitinib, -placebo, and -apremilast, respectively)”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary outcome in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary outcome measure | “To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study” |
| Measure description and time frame | “Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) Approximately 4 years” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.6.1-2"></a>

##### Secondary outcomes in the ClinicalTrials.gov record

| Secondary outcome measure | Measure description and time frame |
| --- | --- |
| “To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-75)” | “Proportion of patients achieving ≥75% reduction in PASI 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-90)” | “Proportion of patients achieving ≥90% reduction in PASI 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 using the Psoriasis Area and Severity Index (PASI-100)” | “Proportion of patients achieving 100% reduction in PASI 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 using the Static Physician's Global Assessment (sPGA 0/1)” | “Proportion of patients achieving a score of 0 or 1 on sPGA 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 based on change in Psoriasis Area and Severity Index (PASI)” | “Change in Psoriasis Area and Severity Index (PASI) from baseline assessments 24, 48, 72, and 96 weeks” |
| “To assess the long-term efficacy of ESK-001 based on change in Affected Body Surface Area (%BSA)” | “Change in affected body surface area (%BSA) from baseline assessments 24, 48, 72, and 96 weeks” |
| “To characterize the loss of PASI-75 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)” | “Median time to loss of PASI-75 response Week 48” |
| “To characterize the loss of PASI-90 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)” | “Median time to loss of PASI-90 response Week 48” |
| “To characterize the loss of sPGA-0/1 response following withdrawal of ESK-001 treatment (only for patients randomized to the treatment withdrawal phase)” | “Median time to loss of sPGA-0/1 response Week 48” |
| “To assess the change in quality of life (QoL) using Dermatology Life Quality Index after long-term ESK-001 administration” | “Proportion of patients achieving a DLQI-0/1 score of 0 (no effect) or 1 (minimal effect) Week 24, Week 48, and Week 72” |

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.6.1-3"></a>

##### Regulatory guidance on the size of the safety database for long-term treatment of non-life-threatening conditions

> “The objective of this guideline is to present an accepted set of principles for the safety evaluation of drugs intended for the long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening diseases.”
> “The safety evaluation during clinical drug development is expected to characterise and quantify the safety profile of a drug over a reasonable duration of time consistent with the intended long-term use of the drug.”
> “To achieve this objective the cohort of exposed subjects should be large enough to observe whether more frequently occurring events increase or decrease over time as well as to observe delayed events of reasonable frequency (e.g., in the general range of 0.5%-5%). Usually 300-600 patients should be adequate.”

Source: [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Estimated enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 1680”

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541)

<a id="topic-3.1.3.7.1-2"></a>

##### Participants who entered ONWARD3 from ONWARD1 or ONWARD2, all entrants

> “A total of 1,509 patients entered ONWARD3 from ONWARD1 or ONWARD2, reflecting a robust rollover rate of >85%.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.7.1-3"></a>

##### Participants entering ONWARD3 by parent-study arm in the congress poster

> “Envudeucitinib → Envudeucitinib (n = 773)”
> “Placebo → Envudeucitinib (n = 367)”
> “Apremilast → Envudeucitinib (n = 369)”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Non-responder imputation analysis set of 773 participants from the envudeucitinib arms

> “A non-responder imputation (NRI) analysis was conducted in 773 of these patients from the envudeucitinib arms and who received up to 48 weeks of continuous treatment (24 weeks in ONWARD1/2 and up to 24 weeks in ONWARD3).”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.7.2-2"></a>

##### Maintenance-of-response populations, restricted subgroups, imputation, and confidence intervals in the congress poster

> “Maintenance of response assessed among patients that achieved a response at entry in ONWARD3 and maintained it after 48 weeks of continuous envudeucitinib for each respective endpoint”
> “Baseline response rates for ONWARD3 encompass 24 weeks treatment duration in ONWARD1 and 2 (Figure 2); PASI 90, 100, and NRS endpoints defined as long-term improvement, and analyses of ss-PGA, NRS, and DLQI are restricted to patients with parent baseline ss-PGA ≥3, NRS ≥4, and DLQI ≥2”
> “Nonresponse imputation applied; analyses are descriptive”
> “The 95% CIs for each arm’s proportion are obtained using Clopper-Pearson methods”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Enrollment of participants who completed week 24 of ONWARD1 or ONWARD2 and consented

> “Patients who completed Week 24 of ONWARD1 or 2, and consented were enrolled in ONWARD3”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Baseline characteristics at ONWARD3 entry by parent-study arm

| Characteristic | Envudeucitinib then envudeucitinib (n = 773) | Placebo then envudeucitinib (n = 367) | Apremilast then envudeucitinib (n = 369) |
| --- | --- | --- | --- |
| Envudeucitinib exposure at start of ONWARD3, weeks | “24” | “8” | “0” |
| Age, years, mean (SD) | “49.6 (13.2)” | “50.6 (13.3)” | “49.1 (12.4)” |
| Duration of disease, years, mean (SD) | “20.2 (13.5)” | “20.1 (13.8)” | “19.0 (13.0)” |
| Prior systemic psoriasis treatment, n (%) | “395 (51.1)” | “185 (50.4)” | “186 (50.4)” |
| PASI, mean (SD) | “1.9 (3.6)” | “4.5 (5.5)” | “6.7 (7.0)” |
| ss-PGA ≥3, n (%) | “18 (2.3)” | “21 (5.7)” | “58 (15.7)” |
| BSA % affected, mean (SD) | “3.8 (7.7)” | “9.4 (12.3)” | “10.7 (13.2)” |
| Worst pruritus NRS score, mean (SD) | “1.3 (1.9)” | “2.0 (2.3)” | “3.1 (2.8)” |
| DLQI, mean (SD) | “1.8 (3.1)” | “2.9 (3.8)” | “4.0 (4.9)” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.2-2"></a>

##### Demographics at ONWARD3 entry compared with the parent-trial population

> “Demographics at ONWARD3 entry were consistent with the overall ONWARD1 and 2 population”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Week 48 PASI 90 and PASI 100 and maintenance among entry responders, NRI analysis of 773 participants

> “75% and 54% of patients achieved PASI 90 and PASI 100, respectively”
> “Among patients who entered ONWARD3 with PASI 90 and PASI 100 responses, approximately 90% and 80%, respectively, sustained their skin clearance for the reported duration of the extension study”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.8.3-2"></a>

##### Week 48 PASI and sPGA responses with continuous envudeucitinib in the congress poster

> “At Week 48, 85.2% of those continuously treated with envudeucitinib achieved PASI 75”
> “At Week 48, 75.2% and 54.5% treated continuously with envudeucitinib achieved almost clear (sPGA-0/1) or clear skin (sPGA-0)”
> “Skin clearance similarly increased in patients switching from placebo or apremilast, approaching rates in continuously treated patients”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.3-3"></a>

##### Maintenance of skin and scalp response at 48 weeks among ONWARD1 and ONWARD2 responders

| Endpoint | Achieved response at the end of ONWARD1 and 2, n | Maintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI) |
| --- | --- | --- |
| PASI 75 | “678” | “89.8 (87.3, 92.0)” |
| PASI 90 | “575” | “89.4 (86.6, 91.8)” |
| sPGA-0/1 | “584” | “87.5 (84.5, 90.1)” |
| PASI 100 | “357” | “80.1 (75.6, 84.1)” |
| sPGA-0 | “365” | “79.5 (74.9, 83.5)” |
| ss-PGA-0/1, among patients with parent baseline ss-PGA ≥3 | “418” | “89.5 (86.1, 92.2)” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.3-4"></a>

##### Scalp clearance at 48 weeks and response after crossover from placebo or apremilast

> “Over 80% of patients in ONWARD3 maintained clear or almost clear scalp skin (scalp-specific Physician Global Assessment [ss-PGA] 0/1) at 48 weeks.”
> “Patients switching from placebo or apremilast achieved rapid improvements across primary and key secondary endpoints, comparable to those continuously treated at Week 48”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.3.8.3-5"></a>

##### Integrated NRI analysis of 890 participants originally randomized to envudeucitinib across ONWARD1, ONWARD2, and ONWARD3

> “Results from a separate integrated NRI analysis across the ONWARD program (ONWARD1/2 and 3)—evaluating 890 patients originally randomized to envudeucitinib in ONWARD1/2, including those who did not transition into ONWARD3—demonstrated that 66% and 47% of patients who received 48 weeks of envudeucitinib achieved PASI 90 and PASI 100, respectively.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

##### Itch and DLQI at 48 weeks, NRI analysis of 773 participants from the envudeucitinib arms

> “In ONWARD3, nearly 80% of patients sustained clinically meaningful itch reduction through Week 48.”
> “In ONWARD3, more than 70% of patients maintained DLQI 0/1 at 48 weeks.”
> “ONWARD3: N=1,509, data reported from non-responder imputation analysis in 773 patients from envudeucitinib arms who received up to 48 weeks of continuous treatment (24 weeks in ONWARD1/2 and up to 24 weeks in ONWARD3).”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-3.1.3.8.4-2"></a>

##### Maintenance of itch and DLQI response at 48 weeks among ONWARD1 and ONWARD2 responders

| Endpoint | Achieved response at the end of ONWARD1 and 2, n | Maintained response after 24 weeks in ONWARD3 (48 weeks of total exposure), % (95% CI) |
| --- | --- | --- |
| At least 4-point improvement from parent baseline in NRS worst pruritus, among patients with parent baseline NRS worst score ≥4 | “509” | “86.2 (82.9, 89.1)” |
| DLQI-0/1, among patients with parent baseline DLQI ≥2 | “497” | “86.3 (83.0, 89.2)” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.4-3"></a>

##### Itch and quality-of-life conclusions of the congress poster

> “Nearly 80% of patients reported clinically-meaningful improvements in itch and >70% demonstrated sustained quality of life improvements”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Adverse events with exposure-adjusted incidence rates by parent-study arm through week 48

| Event | Envudeucitinib then envudeucitinib (n = 773), n (%) | EAIR | Placebo then envudeucitinib (n = 367), n (%) | EAIR | Apremilast then envudeucitinib (n = 369), n (%) | EAIR |
| --- | --- | --- | --- | --- | --- | --- |
| At least 1 TEAE | “521 (67.4)” | “177.9” | “253 (68.9)” | “185.4” | “268 (72.6)” | “219.2” |
| At least 1 SAE | “25 (3.2)” | “4.7” | “16 (4.4)” | “6.3” | “9 (2.4)” | “3.6” |
| TEAEs grade ≥3 | “45 (5.8)” | “8.6” | “31 (8.4)” | “12.5” | “16 (4.3)” | “6.5” |
| TEAEs leading to discontinuation | “23 (3.0)” | “4.3” | “11 (3.0)” | “4.2” | “25 (6.8)” | “10.1” |
| Related TEAEs | “104 (13.5)” | “21” | “52 (14.2)” | “21.7” | “82 (22.2)” | “37.9” |
| Nasopharyngitis | “109 (14.1)” | “22.2” | “67 (18.3)” | “28.8” | “44 (11.9)” | “19” |
| Upper respiratory tract infection | “92 (11.9)” | “18.4” | “44 (12.0)” | “18.1” | “44 (11.9)” | “18.7” |
| Influenza | “34 (4.4)” | “6.5” | “19 (5.2)” | “7.5” | “17 (4.6)” | “6.9” |
| Urinary tract infection | “37 (4.8)” | “7.1” | “9 (2.5)” | “3.5” | “13 (3.5)” | “5.3” |
| Acne | “14 (1.8)” | “2.6” | “9 (2.5)” | “3.5” | “18 (4.9)” | “7.5” |

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.5-2"></a>

##### Patient-years of exposure, exposure basis of the incidence rates, deaths, MACE, laboratory abnormalities, malignancies, and tuberculosis

> “Total patient years, years 532.6 259.7 249.6”
> “EAIR is based on exposure in ONWARD 3 only.”
> “Majority of TEAEs were non-serious, grade 1 and 2, resolved and did not lead to study discontinuation”
> “There were no deaths, no MACE events, no clinically significant lab abnormalities, no lymphomas, and no tuberculosis reactivation”
> “Three positive tuberculosis tests were reported with no clinical signs or symptoms; none discontinued study treatment.”
> “Malignancies and serious infections occurred at rates consistent with expected background rates in a psoriasis population”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.8.5-3"></a>

##### Safety compared with ONWARD1 and ONWARD2 in the topline release

> “Treatment with envudeucitinib in ONWARD3 continued to be well tolerated, with a safety profile consistent with ONWARD1/2 and no new safety signals observed.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

<a id="topic-3.1.3.8.5-4"></a>

##### Safety with long-term exposure in the Fall Clinical release

> “No new safety signals were observed with long-term exposure in ONWARD3.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

- Results of the randomized treatment withdrawal period, which began after 24 weeks for the first 200 participants, are “data not reported” in the congress poster.
- All participants received open-label envudeucitinib during the first 24 weeks, with no concurrent control group; regulatory guidance states that the absence of a concurrent control group makes it more difficult to assess the causality relationship between adverse events and the drug.
- Entry required completion of week 24 of a parent trial, consent, and acceptable safety and tolerability of the drug in the parent study. The maintenance analyses are restricted to participants who had a response at entry, and the poster states that the analyses are descriptive.
- Envudeucitinib exposure at week 48 differed by parent-study arm (48, 32, and 24 weeks), and the exposure-adjusted incidence rates are based on exposure in ONWARD3 only.
- Week 48 PASI 90 and PASI 100 rates come from two analyses: a non-responder imputation analysis of 773 entrants (75% and 54%) and an integrated non-responder imputation analysis of 890 participants originally randomized to envudeucitinib (66% and 47%).
- Enrollment is reported as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 by parent-study arm (poster).
- The poster describes malignancies and serious infections as occurring at rates consistent with expected background rates without giving counts, and the report holds no ONWARD3 participant disposition beyond study entry.
- The study is ongoing, with primary completion estimated for 2028-11.

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541); [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm); [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf); [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

<a id="topic-3.1.3.9-2"></a>

#### Randomized withdrawal period results not reported in the congress poster

> “Randomized treatment withdrawal period began after 24 weeks in ONWARD3 for first 200 patients; data not reported”

Source: [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-3.1.3.9-3"></a>

#### Regulatory guidance on causality assessment in studies without a concurrent control group

> “A study that has no concurrent control group makes it more difficult to assess the causality relationship between adverse events observed and the test drug.”

Source: [ICH E1 population exposure guideline (1995)](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-1-population-exposure-extent-population-exposure-assess-clinical-safety-step-5_en.pdf)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
